Layn(002166)2025-01-21 11:10Financial Performance - The company expects a net profit attributable to shareholders to be between 156.77 million and 189.78 million CNY, representing a year-on-year growth of 90% to 130%[3] - The net profit after deducting non-recurring gains and losses is projected to be between 143.16 million and 176.17 million CNY, indicating a year-on-year increase of 594% to 755%[3] - Basic earnings per share are estimated to be between 0.22 CNY and 0.26 CNY, compared to 0.11 CNY in the same period last year[3] - The financial data provided is preliminary and subject to final confirmation in the 2024 annual report[7] Business Development - The company has successfully completed the construction of new production capacity and achieved breakthroughs in the synthetic biology field, laying a solid foundation for long-term healthy development[5] - The company continues to implement a major product development strategy and enhance global market expansion efforts, focusing on deepening customer application potential[5] Market Position and Reputation - The brand reputation of the company has improved, gaining recognition from an increasing number of domestic and international brand clients[6] - The company has enhanced cooperation with domestic and foreign customers, increasing market share and improving internal management efficiency[6]